Current Environment: Production

Medical Services

Programs & Services

Education

Medical School

University of Texas Southwestern Medical School

1996, Dallas, TX

Internship

Boston Combined Residency Program (BCRP)

1998, Boston, MA

Residency

Boston Combined Residency Program (BCRP)

1998, Boston, MA

Fellowship

Dana-Farber/Boston Children's Cancer and Blood Disorders Center

2001, Boston, MA

Professional History

Scott A. Armstrong, MD, PhD, became the President of Dana-Farber/Boston Children’s Cancer and Blood Disorders Center in 2019 and has been Chairman of the Department of Pediatric Oncology at Dana-Farber Cancer Institute since 2016. He also serves as Associate Chief of the Division of Hematology/Oncology at Boston Children’s Hospital. He was previously the Director of the Center for Epigenetics Research at Memorial Sloan Kettering Cancer Center and Professor of Pediatrics at the Weill Cornell Medical College. Dr. Armstrong earned his medical degree and his PhD from University of Texas Southwestern Medical School in 1996. After internship and residency training with the Boston Combined Residency Program (BCRP) at Boston Medical Center and Boston Children’s Hospital, he completed a hematology/oncology fellowship at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center.

The major focus of his career has been on delineating the biology of childhood cancers and the development of new therapeutic approaches for children with cancer. His research program has focused on the mechanisms of leukemia development and the relationship between leukemia and normal hematopoietic stem cells. He continues to direct a vigorous research program that focuses on development of new therapeutics that target chromatin based mechanisms, and he is actively involved in the development and translation of a number of new small molecule approaches that likely will be tested in clinical trials in the near future.

Publications

  1. The Prolonged Half-Life of the p53 Missense Variant R248Q Promotes Accumulation and Heterotetramer Formation with Wildtype p53 to Exert the Dominant-Negative Effect. Cancer Res. 2025 Mar 31. View Abstract

  2. Targeting the Menin-KMT2A interaction in leukemia: Lessons learned and future directions. Int J Cancer. 2025 Jan 30. View Abstract

  3. Epigenetic Therapies. Cold Spring Harb Perspect Med. 2024 Dec 18. View Abstract

  4. Catalytic inhibition of KAT6/KAT7 enhances the efficacy and overcomes primary and acquired resistance to Menin inhibitors in MLL leukaemia. bioRxiv. 2024 Dec 12. View Abstract

  5. Revumenib Revises the Treatment Landscape for KMT2A-r Leukemia. J Clin Oncol. 2025 Jan; 43(1):85-88. View Abstract

  6. NUP98 fusion proteins and KMT2A-MENIN antagonize PRC1.1 to drive gene expression in AML. Cell Rep. 2024 11 26; 43(11):114901. View Abstract

  7. CRISPR Dependency Screens in Primary Hematopoietic Stem Cells Identify KDM3B as a Genotype-specific Vulnerability in IDH2- and TET2-mutant Cells. Cancer Discov. 2024 Oct 04; 14(10):1860-1878. View Abstract

  8. Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias. Blood. 2024 09 12; 144(11):1206-1220. View Abstract

  9. A MOZ-TIF2 leukemia mouse model displays KAT6-dependent H3K23 propionylation and overexpression of a set of active developmental genes. Proc Natl Acad Sci U S A. 2024 Jun 25; 121(26):e2405905121. View Abstract

  10. PI3K? maintains the self-renewal of acute myeloid leukemia stem cells by regulating the pentose phosphate pathway. Blood. 2024 05 09; 143(19):1965-1979. View Abstract

  11. Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AML. Blood. 2024 04 11; 143(15):1513-1527. View Abstract

  12. Therapeutic targeting Tudor domains in leukemia via CRISPR-Scan Assisted Drug Discovery. Sci Adv. 2024 Feb 23; 10(8):eadk3127. View Abstract

  13. Inherited blood cancer predisposition through altered transcription elongation. Cell. 2024 Feb 01; 187(3):642-658.e19. View Abstract

  14. Immunoproteasome function maintains oncogenic gene expression in KMT2A-complex driven leukemia. Mol Cancer. 2023 12 04; 22(1):196. View Abstract

  15. The future of HOXA- expressing leukemias: Menin inhibitor response and resistance. Curr Opin Hematol. 2024 03 01; 31(2):64-70. View Abstract

  16. Epitope editing enables targeted immunotherapy of acute myeloid leukaemia. Nature. 2023 Sep; 621(7978):404-414. View Abstract

  17. KDM6A epigenetically regulates subtype plasticity in small cell lung cancer. Nat Cell Biol. 2023 09; 25(9):1346-1358. View Abstract

  18. UBR5 forms ligand-dependent complexes on chromatin to regulate nuclear hormone receptor stability. Mol Cell. 2023 08 03; 83(15):2753-2767.e10. View Abstract

  19. MLL3 regulates the CDKN2A tumor suppressor locus in liver cancer. Elife. 2023 06 01; 12. View Abstract

  20. MEN1 mutations mediate clinical resistance to menin inhibition. Nature. 2023 03; 615(7954):913-919. View Abstract

  21. The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature. 2023 03; 615(7954):920-924. View Abstract

  22. Mutant NPM1 Directly Regulates Oncogenic Transcription in Acute Myeloid Leukemia. Cancer Discov. 2023 03 01; 13(3):746-765. View Abstract

  23. A Molecular Switch between Mammalian MLL Complexes Dictates Response to Menin-MLL Inhibition. Cancer Discov. 2023 01 09; 13(1):146-169. View Abstract

  24. SETD2 Haploinsufficiency Enhances Germinal Center-Associated AICDA Somatic Hypermutation to Drive B-cell Lymphomagenesis. Cancer Discov. 2022 07 06; 12(7):1782-1803. View Abstract

  25. MOZ and Menin-MLL Complexes Are Complementary Regulators of Chromatin Association and Transcriptional Output in Gastrointestinal Stromal Tumor. Cancer Discov. 2022 07 06; 12(7):1804-1823. View Abstract

  26. IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia. Nat Cancer. 2022 05; 3(5):595-613. View Abstract

  27. Antigen presentation safeguards the integrity of the hematopoietic stem cell pool. Cell Stem Cell. 2022 05 05; 29(5):760-775.e10. View Abstract

  28. Bone Marrow Surveillance of Pediatric Cancer Survivors Identifies Clones that Predict Therapy-Related Leukemia. Clin Cancer Res. 2022 04 14; 28(8):1614-1627. View Abstract

  29. MLL::AF9 degradation induces rapid changes in transcriptional elongation and subsequent loss of an active chromatin landscape. Mol Cell. 2022 03 17; 82(6):1140-1155.e11. View Abstract

  30. The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML. Blood. 2022 02 10; 139(6):894-906. View Abstract

  31. Menin Inhibitors in Acute Myeloid Leukemia-What Does the Future Hold? Cancer J. 2022 Jan-Feb 01; 28(1):62-66. View Abstract

  32. YBX1 mediates translation of oncogenic transcripts to control cell competition in AML. Leukemia. 2022 02; 36(2):426-437. View Abstract

  33. Evaluation of the Efficacy of Doxycycline, Ciprofloxacin, Levofloxacin, and Co-trimoxazole Using In Vitro and In Vivo Models of Q Fever. Antimicrob Agents Chemother. 2021 10 18; 65(11):e0067321. View Abstract

  34. Taspase1 orchestrates fetal liver hematopoietic stem cell and vertebrae fates by cleaving TFIIA. JCI Insight. 2021 08 09; 6(15). View Abstract

  35. High-resolution characterization of gene function using single-cell CRISPR tiling screen. Nat Commun. 2021 07 01; 12(1):4063. View Abstract

  36. A JAK/STAT-mediated inflammatory signaling cascade drives oncogenesis in AF10-rearranged AML. Blood. 2021 06 17; 137(24):3403-3415. View Abstract

  37. Histone PTM Crosstalk Stimulates Dot1 Methyltransferase Activity. Trends Biochem Sci. 2021 07; 46(7):522-524. View Abstract

  38. Pathological angiogenesis in retinopathy engages cellular senescence and is amenable to therapeutic elimination via BCL-xL inhibition. Cell Metab. 2021 04 06; 33(4):818-832.e7. View Abstract

  39. HAND1 and BARX1 Act as Transcriptional and Anatomic Determinants of Malignancy in Gastrointestinal Stromal Tumor. Clin Cancer Res. 2021 03 15; 27(6):1706-1719. View Abstract

  40. Targeting Chromatin Complexes in Myeloid Malignancies and Beyond: From Basic Mechanisms to Clinical Innovation. Cells. 2020 12 21; 9(12). View Abstract

  41. Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition. Blood. 2020 11 19; 136(21):2442-2456. View Abstract

  42. Author Correction: PGBD5 promotes site-specific oncogenic mutations in human tumors. Nat Genet. 2020 Nov; 52(11):1265. View Abstract

  43. Novel inhibitors of the histone methyltransferase DOT1L show potent antileukemic activity in patient-derived xenografts. Blood. 2020 10 22; 136(17):1983-1988. View Abstract

  44. Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. Eur J Cancer. 2020 11; 139:135-148. View Abstract

  45. Leukemia Cell of Origin Influences Apoptotic Priming and Sensitivity to LSD1 Inhibition. Cancer Discov. 2020 10; 10(10):1500-1513. View Abstract

  46. It's Not What You Say But How You Say It: Targeting RNA Methylation in AML. Mol Cell. 2020 06 18; 78(6):996-998. View Abstract

  47. Chromatin Complexes Maintain Self-Renewal of Myeloid Progenitors in AML: Opportunities for Therapeutic Intervention. Stem Cell Reports. 2020 07 14; 15(1):6-12. View Abstract

  48. Oncogenic Gene-Expression Programs in Leiomyosarcoma and Characterization of Conventional, Inflammatory, and Uterogenic Subtypes. Mol Cancer Res. 2020 09; 18(9):1302-1314. View Abstract

  49. Higher-Order Linearization and Regularity in Nonlinear Homogenization. Arch Ration Mech Anal. 2020; 237(2):631-741. View Abstract

  50. Loss of H3K36 Methyltransferase SETD2 Impairs V(D)J Recombination during Lymphoid Development. iScience. 2020 Mar 27; 23(3):100941. View Abstract

  51. Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia. Science. 2020 01 31; 367(6477):586-590. View Abstract

  52. A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia. Cancer Cell. 2019 12 09; 36(6):660-673.e11. View Abstract

  53. Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia. Cancer Discov. 2020 02; 10(2):214-231. View Abstract

  54. A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies. Science. 2019 08 09; 365(6453):599-604. View Abstract

  55. Rationale for targeting BCL6 in MLL-rearranged acute lymphoblastic leukemia. Genes Dev. 2019 09 01; 33(17-18):1265-1279. View Abstract

  56. Acute myeloid leukemia driven by the CALM-AF10 fusion gene is dependent on BMI1. Exp Hematol. 2019 06; 74:42-51.e3. View Abstract

  57. Targeting chromatin complexes in fusion protein-driven malignancies. Nat Rev Cancer. 2019 05; 19(5):255-269. View Abstract

  58. Enhancer Domains in Gastrointestinal Stromal Tumor Regulate KIT Expression and Are Targetable by BET Bromodomain Inhibition. Cancer Res. 2019 03 01; 79(5):994-1009. View Abstract

  59. IKZF2 Drives Leukemia Stem Cell Self-Renewal and Inhibits Myeloid Differentiation. Cell Stem Cell. 2019 01 03; 24(1):153-165.e7. View Abstract

  60. Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma. Elife. 2018 11 15; 7. View Abstract

  61. Inhibition of MEK and ATR is effective in a B-cell acute lymphoblastic leukemia model driven by Mll-Af4 and activated Ras. Blood Adv. 2018 10 09; 2(19):2478-2490. View Abstract

  62. Improved potency and reduced toxicity of the antifungal peptoid AEC5 through submonomer modification. Bioorg Med Chem Lett. 2018 12 01; 28(22):3514-3519. View Abstract

  63. HOXA9 Reprograms the Enhancer Landscape to Promote Leukemogenesis. Cancer Cell. 2018 10 08; 34(4):643-658.e5. View Abstract

  64. Location, Location, Location: Mutant NPM1c Cytoplasmic Localization Is Required to Maintain Stem Cell Genes in AML. Cancer Cell. 2018 09 10; 34(3):355-357. View Abstract

  65. Gastrointestinal stromal tumor enhancers support a transcription factor network predictive of clinical outcome. Proc Natl Acad Sci U S A. 2018 06 19; 115(25):E5746-E5755. View Abstract

  66. The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia. Blood. 2018 06 14; 131(24):2661-2669. View Abstract

  67. A Non-catalytic Function of SETD1A Regulates Cyclin K and the DNA Damage Response. Cell. 2018 02 22; 172(5):1007-1021.e17. View Abstract

  68. LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBPa-dependent enhancers in AML. Blood. 2018 04 12; 131(15):1730-1742. View Abstract

  69. MEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid Leukemia. Cancer Discov. 2018 04; 8(4):478-497. View Abstract

  70. Peptidomimetic blockade of MYB in acute myeloid leukemia. Nat Commun. 2018 01 09; 9(1):110. View Abstract

  71. Mixed-Lineage Leukemia Fusions and Chromatin in Leukemia. Cold Spring Harb Perspect Med. 2017 Nov 01; 7(11). View Abstract

  72. SETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia. Blood. 2017 12 14; 130(24):2631-2641. View Abstract

  73. Erratum: PGBD5 promotes site-specific oncogenic mutations in human tumors. Nat Genet. 2017 09 27; 49(10):1558. View Abstract

  74. miR-99 regulates normal and malignant hematopoietic stem cell self-renewal. J Exp Med. 2017 Aug 07; 214(8):2453-2470. View Abstract

  75. A UTX-MLL4-p300 Transcriptional Regulatory Network Coordinately Shapes Active Enhancer Landscapes for Eliciting Transcription. Mol Cell. 2017 Jul 20; 67(2):308-321.e6. View Abstract

  76. PGBD5 promotes site-specific oncogenic mutations in human tumors. Nat Genet. 2017 Jul; 49(7):1005-1014. View Abstract

  77. Functional screen of MSI2 interactors identifies an essential role for SYNCRIP in myeloid leukemia stem cells. Nat Genet. 2017 Jun; 49(6):866-875. View Abstract

  78. Degradation of the BAF Complex Factor BRD9 by Heterobifunctional Ligands. Angew Chem Int Ed Engl. 2017 05 15; 56(21):5738-5743. View Abstract

  79. Deletion of ribosomal protein genes is a common vulnerability in human cancer, especially in concert with TP53 mutations. EMBO Mol Med. 2017 04; 9(4):498-507. View Abstract

  80. Myeloid progenitor cluster formation drives emergency and leukaemic myelopoiesis. Nature. 2017 04 06; 544(7648):53-58. View Abstract

  81. PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D. Science. 2017 03 24; 355(6331):1324-1330. View Abstract

  82. ENL links histone acetylation to oncogenic gene expression in acute myeloid leukaemia. Nature. 2017 03 09; 543(7644):265-269. View Abstract

  83. Histone Acetyltransferase Activity of MOF Is Required for MLL-AF9 Leukemogenesis. Cancer Res. 2017 04 01; 77(7):1753-1762. View Abstract

  84. NUP98 Fusion Proteins Interact with the NSL and MLL1 Complexes to Drive Leukemogenesis. Cancer Cell. 2016 Dec 12; 30(6):863-878. View Abstract

  85. DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling. Nat Med. 2016 12; 22(12):1488-1495. View Abstract

  86. Controlled stem cell amplification by HOXB4 depends on its unique proline-rich region near the N terminus. Blood. 2017 01 19; 129(3):319-323. View Abstract

  87. Histone acetyltransferase activity of MOF is required for adult but not early fetal hematopoiesis in mice. Blood. 2017 01 05; 129(1):48-59. View Abstract

  88. Discovery and Characterization of a Peptoid with Antifungal Activity against Cryptococcus neoformans. ACS Med Chem Lett. 2016 Dec 08; 7(12):1139-1144. View Abstract

  89. AACR Cancer Progress Report 2016. Clin Cancer Res. 2016 10 01; 22 Suppl 19:S1-S137. View Abstract

  90. Targeting the kinase activities of ATR and ATM exhibits antitumoral activity in mouse models of MLL-rearranged AML. Sci Signal. 2016 09 13; 9(445):ra91. View Abstract

  91. Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia. Cancer Discov. 2016 10; 6(10):1166-1181. View Abstract

  92. Forward genetic screen of human transposase genomic rearrangements. BMC Genomics. 2016 Aug 04; 17:548. View Abstract

  93. The UK Neovascular AMD Database Report 3: inter-centre variation in visual acuity outcomes and establishing real-world measures of care. Eye (Lond). 2016 Nov; 30(11):1462-1468. View Abstract

  94. Patient-derived xenotransplants can recapitulate the genetic driver landscape of acute leukemias. Leukemia. 2017 01; 31(1):151-158. View Abstract

  95. Reply to "Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status". Nat Med. 2016 06 07; 22(6):578-9. View Abstract

  96. Erratum: Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins. Nat Med. 2016 06 07; 22(6):692. View Abstract

  97. The role of DOT1L in the maintenance of leukemia gene expression. Curr Opin Genet Dev. 2016 02; 36:68-72. View Abstract

  98. Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins. Nat Med. 2016 06; 22(6):672-8. View Abstract

  99. Exploiting the Epigenome to Control Cancer-Promoting Gene-Expression Programs. Cancer Cell. 2016 Apr 11; 29(4):464-476. View Abstract

  100. Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting. Blood. 2016 06 16; 127(24):3004-14. View Abstract

  101. MLL1 and DOT1L cooperate with meningioma-1 to induce acute myeloid leukemia. J Clin Invest. 2016 Apr 01; 126(4):1438-50. View Abstract

  102. Ezh2 Controls an Early Hematopoietic Program and Growth and Survival Signaling in Early T Cell Precursor Acute Lymphoblastic Leukemia. Cell Rep. 2016 Mar 01; 14(8):1953-65. View Abstract

  103. MLL-AF9- and HOXA9-mediated acute myeloid leukemia stem cell self-renewal requires JMJD1C. J Clin Invest. 2016 Mar 01; 126(3):997-1011. View Abstract

  104. Editorial overview: Differentiation and disease. Curr Opin Cell Biol. 2015 Dec; 37:v-vi. View Abstract

  105. Drugging Chromatin in Cancer: Recent Advances and Novel Approaches. Mol Cell. 2015 Nov 19; 60(4):561-70. View Abstract

  106. A chromatin-independent role of Polycomb-like 1 to stabilize p53 and promote cellular quiescence. Genes Dev. 2015 Nov 01; 29(21):2231-43. View Abstract

  107. Impact of FLT3-ITD location on sensitivity to TKI-therapy in vitro and in vivo. Leukemia. 2016 05; 30(5):1220-1225. View Abstract

  108. JMJD1C is required for the survival of acute myeloid leukemia by functioning as a coactivator for key transcription factors. Genes Dev. 2015 Oct 15; 29(20):2123-39. View Abstract

  109. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015 Nov 26; 126(22):2479-83. View Abstract

  110. Loss of BAP1 function leads to EZH2-dependent transformation. Nat Med. 2015 Nov; 21(11):1344-9. View Abstract

  111. The PZP Domain of AF10 Senses Unmodified H3K27 to Regulate DOT1L-Mediated Methylation of H3K79. Mol Cell. 2015 Oct 15; 60(2):319-27. View Abstract

  112. Mediator kinase inhibition further activates super-enhancer-associated genes in AML. Nature. 2015 Oct 08; 526(7572):273-276. View Abstract

  113. Hematopoietic Differentiation Is Required for Initiation of Acute Myeloid Leukemia. Cell Stem Cell. 2015 Nov 05; 17(5):611-23. View Abstract

  114. Inactivation of Eed impedes MLL-AF9-mediated leukemogenesis through Cdkn2a-dependent and Cdkn2a-independent mechanisms in a murine model. Exp Hematol. 2015 Nov; 43(11):930-935.e6. View Abstract

  115. Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyond. Exp Hematol. 2015 Aug; 43(8):673-84. View Abstract

  116. Designed to kill: novel menin-MLL inhibitors target MLL-rearranged leukemia. Cancer Cell. 2015 Apr 13; 27(4):431-3. View Abstract

  117. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia. Nat Med. 2015 Apr; 21(4):335-43. View Abstract

  118. Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL. Clin Cancer Res. 2015 May 15; 21(10):2348-58. View Abstract

  119. MLL partial tandem duplication leukemia cells are sensitive to small molecule DOT1L inhibition. Haematologica. 2015 May; 100(5):e190-3. View Abstract

  120. Structure-guided DOT1L probe optimization by label-free ligand displacement. ACS Chem Biol. 2015 Mar 20; 10(3):667-74. View Abstract

  121. Evolutionarily conserved signaling pathways: acting in the shadows of acute myelogenous leukemia's genetic diversity. Clin Cancer Res. 2015 Jan 15; 21(2):240-8. View Abstract

  122. Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapy. Cell Stem Cell. 2014 Dec 04; 15(6):775-90. View Abstract

  123. Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. Proc Natl Acad Sci U S A. 2014 Dec 16; 111(50):E5401-10. View Abstract

  124. AF10 regulates progressive H3K79 methylation and HOX gene expression in diverse AML subtypes. Cancer Cell. 2014 Dec 08; 26(6):896-908. View Abstract

  125. Erratum: Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies. Sci Data. 2014; 1:140044. View Abstract

  126. Far infrared laser polarimetry and far forward scattering diagnostics for the C-2 field reversed configuration plasmas. Rev Sci Instrum. 2014 Nov; 85(11):11D401. View Abstract

  127. Langmuir probe diagnostic suite in the C-2 field-reversed configuration. Rev Sci Instrum. 2014 Nov; 85(11):11D824. View Abstract

  128. Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies. Sci Data. 2014; 1:140035. View Abstract

  129. Transmembrane Inhibitor of RICTOR/mTORC2 in Hematopoietic Progenitors. Stem Cell Reports. 2014 Nov 11; 3(5):832-40. View Abstract

  130. CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma. Genes Dev. 2014 Aug 15; 28(16):1800-14. View Abstract

  131. DNA-damage-induced differentiation of leukaemic cells as an anti-cancer barrier. Nature. 2014 Oct 02; 514(7520):107-11. View Abstract

  132. Acute myelogenous leukemia-induced sympathetic neuropathy promotes malignancy in an altered hematopoietic stem cell niche. Cell Stem Cell. 2014 Sep 04; 15(3):365-375. View Abstract

  133. Sleep disruption in tetraplegia: a randomised, double-blind, placebo-controlled crossover trial of 3?mg melatonin. Spinal Cord. 2014 Aug; 52(8):629-34. View Abstract

  134. Requirement for CDK6 in MLL-rearranged acute myeloid leukemia. Blood. 2014 Jul 03; 124(1):13-23. View Abstract

  135. Genomic dark matter sheds light on EVI1-driven leukemia. Cancer Cell. 2014 Apr 14; 25(4):407-8. View Abstract

  136. Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia. Nat Commun. 2014 Mar 24; 5:3469. View Abstract

  137. Evidence of the biochemical basis of host virulence in the greenbug aphid, Schizaphis graminum (Homoptera: Aphididae). J Proteome Res. 2014 Apr 04; 13(4):2094-108. View Abstract

  138. Targeting epigenetic regulators for cancer therapy. Ann N Y Acad Sci. 2014 Feb; 1309:30-6. View Abstract

  139. Stem cells: Dual response to Ras mutation. Nature. 2013 Dec 05; 504(7478):91-2. View Abstract

  140. KRas(G12D)-evoked leukemogenesis does not require ß-catenin. Leukemia. 2014 Mar; 28(3):698-702. View Abstract

  141. Pathprinting: An integrative approach to understand the functional basis of disease. Genome Med. 2013; 5(7):68. View Abstract

  142. In Vivo RNAi screening identifies a leukemia-specific dependence on integrin beta 3 signaling. Cancer Cell. 2013 Jul 08; 24(1):45-58. View Abstract

  143. Recent progress toward epigenetic therapies: the example of mixed lineage leukemia. Blood. 2013 Jun 13; 121(24):4847-53. View Abstract

  144. Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-a in a murine model of polycythemia vera. Blood. 2013 May 02; 121(18):3692-702. View Abstract

  145. DOT1L-mediated H3K79 methylation in chromatin is dispensable for Wnt pathway-specific and other intestinal epithelial functions. Mol Cell Biol. 2013 May; 33(9):1735-45. View Abstract

  146. Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l. Blood. 2013 Mar 28; 121(13):2533-41. View Abstract

  147. Notch pathway activation targets AML-initiating cell homeostasis and differentiation. J Exp Med. 2013 Feb 11; 210(2):301-19. View Abstract

  148. The cell fate determinant Llgl1 influences HSC fitness and prognosis in AML. J Exp Med. 2013 Jan 14; 210(1):15-22. View Abstract

  149. Cell of origin determines clinically relevant subtypes of MLL-rearranged AML. Leukemia. 2013 Apr; 27(4):852-60. View Abstract

  150. Cancer. Can one cell influence cancer heterogeneity? Science. 2012 Nov 23; 338(6110):1035-6. View Abstract

  151. Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l. Leukemia. 2013 Apr; 27(4):813-22. View Abstract

  152. mTOR complex 1 plays critical roles in hematopoiesis and Pten-loss-evoked leukemogenesis. Cell Stem Cell. 2012 Sep 07; 11(3):429-39. View Abstract

  153. Chromatin modifications as therapeutic targets in MLL-rearranged leukemia. Trends Immunol. 2012 Nov; 33(11):563-70. View Abstract

  154. A systemic approach to containing health care spending. N Engl J Med. 2012 Sep 06; 367(10):949-54. View Abstract

  155. EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs. Blood. 2012 Jun 14; 119(24):5838-49. View Abstract

  156. Genetic and pharmacologic inhibition of ß-catenin targets imatinib-resistant leukemia stem cells in CML. Cell Stem Cell. 2012 Apr 06; 10(4):412-24. View Abstract

  157. Polycomb repressive complex 2 is required for MLL-AF9 leukemia. Proc Natl Acad Sci U S A. 2012 Mar 27; 109(13):5028-33. View Abstract

  158. Chromatin-modifying enzymes as modulators of reprogramming. Nature. 2012 Mar 04; 483(7391):598-602. View Abstract

  159. Sequencing histone-modifying enzymes identifies UTX mutations in acute lymphoblastic leukemia. Leukemia. 2012 Aug; 26(8):1881-3. View Abstract

  160. iCanPlot: visual exploration of high-throughput omics data using interactive Canvas plotting. PLoS One. 2012; 7(2):e31690. View Abstract

  161. Haploinsufficiency of Dnmt1 impairs leukemia stem cell function through derepression of bivalent chromatin domains. Genes Dev. 2012 Feb 15; 26(4):344-9. View Abstract

  162. A role for DOT1L in MLL-rearranged leukemias. Epigenomics. 2011 Dec; 3(6):667-70. View Abstract

  163. The Stem Cell Discovery Engine: an integrated repository and analysis system for cancer stem cell comparisons. Nucleic Acids Res. 2012 Jan; 40(Database issue):D984-91. View Abstract

  164. eXframe: reusable framework for storage, analysis and visualization of genomics experiments. BMC Bioinformatics. 2011 Nov 21; 12:452. View Abstract

  165. AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias. Cell. 2011 Sep 02; 146(5):697-708. View Abstract

  166. Self-renewal related signaling in myeloid leukemia stem cells. Int J Hematol. 2011 Aug; 94(2):109-117. View Abstract

  167. Differential niche and Wnt requirements during acute myeloid leukemia progression. Blood. 2011 Sep 08; 118(10):2849-56. View Abstract

  168. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell. 2011 Jul 12; 20(1):53-65. View Abstract

  169. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell. 2011 Jul 12; 20(1):66-78. View Abstract

  170. The clathrin-binding domain of CALM and the OM-LZ domain of AF10 are sufficient to induce acute myeloid leukemia in mice. Leukemia. 2011 Nov; 25(11):1718-27. View Abstract

  171. Cancer: The flipside of Notch. Nature. 2011 May 12; 473(7346):159-60. View Abstract

  172. Crebbp haploinsufficiency in mice alters the bone marrow microenvironment, leading to loss of stem cells and excessive myelopoiesis. Blood. 2011 Jul 07; 118(1):69-79. View Abstract

  173. Common and overlapping oncogenic pathways contribute to the evolution of acute myeloid leukemias. Cancer Res. 2011 Jun 15; 71(12):4117-29. View Abstract

  174. Targeting epigenetic programs in MLL-rearranged leukemias. Hematology Am Soc Hematol Educ Program. 2011; 2011:354-60. View Abstract

  175. Genetics, epigenetics, and leukemia. N Engl J Med. 2010 Dec 16; 363(25):2460-1. View Abstract

  176. DNA methylation profiling in acute myeloid leukemia: from recent technological advances to biological and clinical insights. Future Oncol. 2010 Sep; 6(9):1415-31. View Abstract

  177. The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science. 2010 Mar 26; 327(5973):1650-3. View Abstract

  178. MLL-rearranged B lymphoblastic leukemias selectively express the immunoregulatory carbohydrate-binding protein galectin-1. Clin Cancer Res. 2010 Apr 01; 16(7):2122-30. View Abstract

  179. A novel mutation in the miR-128b gene reduces miRNA processing and leads to glucocorticoid resistance of MLL-AF4 acute lymphocytic leukemia cells. Cell Cycle. 2010 Mar 15; 9(6):1037-42. View Abstract

  180. NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem cell transplantation unrelated to graft-versus-tumor effects: state of the science. Biol Blood Marrow Transplant. 2010 Jun; 16(6):709-28. View Abstract

  181. Teladorsagia circumcincta: activation-associated secreted proteins in excretory/secretory products of fourth stage larvae are targets of early IgA responses in infected sheep. Exp Parasitol. 2010 Aug; 125(4):329-37. View Abstract

  182. HELP for AML: methylation profiling opens new avenues. Cancer Cell. 2010 Jan 19; 17(1):1-3. View Abstract

  183. Association of high-level MCL-1 expression with in vitro and in vivo prednisone resistance in MLL-rearranged infant acute lymphoblastic leukemia. Blood. 2010 Feb 04; 115(5):1018-25. View Abstract

  184. miR-128b is a potent glucocorticoid sensitizer in MLL-AF4 acute lymphocytic leukemia cells and exerts cooperative effects with miR-221. Blood. 2009 Nov 05; 114(19):4169-78. View Abstract

  185. Transformation from committed progenitor to leukemia stem cells. Ann N Y Acad Sci. 2009 Sep; 1176:144-9. View Abstract

  186. Hedgehog signaling is dispensable for adult murine hematopoietic stem cell function and hematopoiesis. Cell Stem Cell. 2009 Jun 05; 4(6):559-67. View Abstract

  187. Chromatin maps, histone modifications and leukemia. Leukemia. 2009 Jul; 23(7):1243-51. View Abstract

  188. Screening and characterization of monoclonal antibodies to the surface antigens of Listeria monocytogenes serotype 4b. J Appl Microbiol. 2009 May; 106(5):1705-14. View Abstract

  189. Mef2C is a lineage-restricted target of Scl/Tal1 and regulates megakaryopoiesis and B-cell homeostasis. Blood. 2009 Apr 09; 113(15):3461-71. View Abstract

  190. Gene expression profiling of leukemia stem cells. Methods Mol Biol. 2009; 538:231-46. View Abstract

  191. Leukemia stem cells and human acute lymphoblastic leukemia. Semin Hematol. 2009 Jan; 46(1):33-8. View Abstract

  192. HOXA9 is required for survival in human MLL-rearranged acute leukemias. Blood. 2009 Mar 12; 113(11):2375-85. View Abstract

  193. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell. 2008 Nov 04; 14(5):355-68. View Abstract

  194. Linking miRNA regulation to BCR-ABL expression: the next dimension. Cancer Cell. 2008 Jun; 13(6):467-9. View Abstract

  195. Cancer: inappropriate expression of stem cell programs? Cell Stem Cell. 2008 Apr 10; 2(4):297-9. View Abstract

  196. Cancer stem cells in hematopoietic malignancies. Biol Blood Marrow Transplant. 2008 Jan; 14(1 Suppl 1):12-6. View Abstract

  197. Cancer Stem Cells in Hematopoietic Malignancies. Biol Blood Marrow Transplant. 2008 Jan; 14(Supplement 1):12-16. View Abstract

  198. BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. Blood. 2008 Feb 15; 111(4):2300-9. View Abstract

  199. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer. 2007 Nov; 7(11):823-33. View Abstract

  200. Defining leukemia stem cells in MLL-translocated leukemias: implications for novel therapeutic strategies. Klin Padiatr. 2007 Nov-Dec; 219(6):306-11. View Abstract

  201. Mixed lineage leukemia translocations and a leukemia stem cell program. Cancer Res. 2007 Sep 15; 67(18):8425-8. View Abstract

  202. MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment. Leukemia. 2008 Jan; 22(1):66-77. View Abstract

  203. Therapeutic implications of leukemia stem cell development. Clin Cancer Res. 2007 Jun 15; 13(12):3439-42. View Abstract

  204. FLT3 as a therapeutic target in childhood acute leukemia. Curr Drug Targets. 2007 Jun; 8(6):703-14. View Abstract

  205. Genome-wide SNP analysis in cancer: leukemia shows the way. Cancer Cell. 2007 Apr; 11(4):308-9. View Abstract

  206. High-throughput oncogene mutation profiling in human cancer. Nat Genet. 2007 Mar; 39(3):347-51. View Abstract

  207. FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell. 2007 Jan 26; 128(2):325-39. View Abstract

  208. Genomewide identification of prednisolone-responsive genes in acute lymphoblastic leukemia cells. Blood. 2007 May 01; 109(9):3929-35. View Abstract

  209. Microarrays to identify new therapeutic strategies for cancer. Adv Cancer Res. 2007; 96:51-74. View Abstract

  210. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006 Sep 29; 313(5795):1929-35. View Abstract

  211. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell. 2006 Oct; 10(4):331-42. View Abstract

  212. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature. 2006 Aug 17; 442(7104):818-22. View Abstract

  213. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell. 2006 May; 9(5):351-65. View Abstract

  214. Silencing of the tumor suppressor gene FHIT is highly characteristic for MLL gene rearranged infant acute lymphoblastic leukemia. Leukemia. 2006 Feb; 20(2):264-71. View Abstract

  215. Gene expression profiling identifies BAX-delta as a novel tumor antigen in acute lymphoblastic leukemia. Cancer Res. 2005 Nov 01; 65(21):10050-8. View Abstract

  216. Distinctive IGH gene segment usage and minimal residual disease detection in infant acute lymphoblastic leukaemias. Br J Haematol. 2005 Oct; 131(2):185-92. View Abstract

  217. Molecular genetics of acute lymphoblastic leukemia. J Clin Oncol. 2005 Sep 10; 23(26):6306-15. View Abstract

  218. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood. 2005 Nov 15; 106(10):3377-9. View Abstract

  219. Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia. Blood. 2005 Oct 01; 106(7):2484-90. View Abstract

  220. Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative disease. EMBO J. 2005 Jan 26; 24(2):368-81. View Abstract

  221. FLT3 mutations in childhood acute lymphoblastic leukemia. Blood. 2004 May 01; 103(9):3544-6. View Abstract

  222. MLL-rearranged leukemias: insights from gene expression profiling. Semin Hematol. 2003 Oct; 40(4):268-73. View Abstract

  223. Comparison of human genomics and genetic models of cancer to identify novel therapeutic targets. Cell Cycle. 2003 Sep-Oct; 2(5):408-9. View Abstract

  224. Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation. Blood. 2003 Jul 01; 102(1):262-8. View Abstract

  225. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell. 2003 Feb; 3(2):173-83. View Abstract

  226. Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia. Blood. 2003 Feb 15; 101(4):1270-6. View Abstract

  227. Genomic approaches to the pathogenesis and treatment of acute lymphoblastic leukemias. Curr Opin Hematol. 2002 Jul; 9(4):339-44. View Abstract

  228. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet. 2002 Jan; 30(1):41-7. View Abstract

  229. Prophylactic platelet transfusions from healthy apheresis platelet donors undergoing treatment with thrombopoietin. Blood. 2001 Sep 01; 98(5):1346-51. View Abstract

  230. Amplification of AML1 in childhood acute lymphoblastic leukemias. Genes Chromosomes Cancer. 2001 Apr; 30(4):407-9. View Abstract

  231. Cytogenetics for the model system Arabidopsis thaliana. Plant J. 1998 Mar; 13(6):867-76. View Abstract

  232. Role and regulation of phospholipase D signalling. Biochem Soc Trans. 1997 Nov; 25(4):1157-60. View Abstract

  233. Casein kinase II-mediated phosphorylation of the C terminus of Sp1 decreases its DNA binding activity. J Biol Chem. 1997 May 23; 272(21):13489-95. View Abstract

  234. Drosophila CBP is a co-activator of cubitus interruptus in hedgehog signalling. Nature. 1997 Apr 17; 386(6626):735-8. View Abstract

  235. Functional expression of low density lipoprotein receptor-related protein is controlled by receptor-associated protein in vivo. Proc Natl Acad Sci U S A. 1995 May 09; 92(10):4537-41. View Abstract

  236. cDNA cloning of component A of Rab geranylgeranyl transferase and demonstration of its role as a Rab escort protein. Cell. 1993 Jun 18; 73(6):1091-9. View Abstract

  237. cDNA cloning and expression of the alpha and beta subunits of rat Rab geranylgeranyl transferase. J Biol Chem. 1993 Jun 05; 268(16):12221-9. View Abstract

  238. The effects of intraarticular administration of hyaluronan in a model of early osteoarthritis in sheep. I. Gait analysis and radiological and morphological studies. Semin Arthritis Rheum. 1993 Jun; 22(6 Suppl 1):18-30. View Abstract

  239. The effects of intraarticular administration of hyaluronan in a model of early osteoarthritis in sheep. II. Cartilage composition and proteoglycan metabolism. Semin Arthritis Rheum. 1993 Jun; 22(6 Suppl 1):31-42. View Abstract

  240. Animal models of early osteoarthritis: their use for the evaluation of potential chondroprotective agents. Agents Actions Suppl. 1993; 39:195-206. View Abstract

  241. The metabolic response of articular cartilage to abnormal mechanical loading induced by medial or lateral meniscectomy. Agents Actions Suppl. 1993; 39:89-93. View Abstract

  242. Breath-actuated inhalers in chronic asthma: comparison of Diskhaler and Turbohaler for delivery of beta-agonists. Eur Respir J. 1992 Oct; 5(9):1143-5. View Abstract

  243. Chondroprotection and NSAIDs. Lancet. 1991 Jun 29; 337(8757):1612-3. View Abstract

  244. In vitro splenic IgG synthesis in Hodgkin's disease. N Engl J Med. 1973 Oct 11; 289(15):763-7. View Abstract
BESbswy